Endeavour Vision

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Virtual Incision is focused on developing innovative surgical solutions, specifically through its miniaturized robotic support device designed for colon resection. The company's flagship product, the MIRA (Miniaturized In vivo Robotic Assistant) Platform, is a pioneering device that aims to streamline surgical procedures by allowing for quick setup in the operating room without the need for heavy equipment. This technology is intended to assist surgeons in improving clinical outcomes while also addressing healthcare costs. Virtual Incision's approach represents a significant advancement in robotic-assisted surgery, with plans for future applications beyond colon resection.

Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

HealthJoy, LLC operates an online healthcare decision platform that aims to reduce out-of-pocket expenses for consumers by enabling better healthcare decisions. Founded in 2014 and based in Chicago, the company focuses on enhancing the benefits experience for employees while assisting organizations in managing costs. Through personalized guidance and AI-driven technology, HealthJoy provides employees with a digital benefits wallet that integrates their existing benefits, ensuring they remain informed about their options. The platform offers on-demand access to online medical consultations, healthcare concierges, and prescription savings, empowering users to make educated choices about their healthcare. By simplifying the healthcare experience and offering insights into cost-effective care options, HealthJoy helps employees improve their satisfaction and reduces the burden on human resources.

IntelyCare, Inc. is a healthcare staffing company based in Quincy, Massachusetts, founded in 2014. It provides an on-demand staffing platform that connects nursing professionals with post-acute healthcare facilities, enabling them to optimize staffing levels and manage workforce demands effectively. The platform allows nurses and nursing assistants to create their own schedules and select shifts that suit them, fostering a flexible work environment. Utilizing advanced data science and artificial intelligence, IntelyCare automates scheduling and improves the efficiency of filling nursing shifts, achieving rates three times the industry average. The company serves a variety of clients, including home care agencies, assisted living facilities, long-term care establishments, and rehabilitation hospitals, ultimately aiming to reduce burnout among nursing staff and enhance overall productivity. IntelyCare operates as a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC.

Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Kenbi is a nurse-centric outpatient care company focused on enhancing healthcare delivery by supporting nurses and addressing gaps in the system. It offers outpatient care management services that leverage technology and a collegial organizational structure to organize local care teams. These teams provide at-home services, which may include medical care covered by insurance, household assistance, advice, and companionship. By streamlining operations and reducing bureaucratic burdens, Kenbi enables healthcare practitioners to devote more time to patient care, thus improving the overall experience for patients and their families.

Virtual Incision is focused on developing innovative surgical solutions, specifically through its miniaturized robotic support device designed for colon resection. The company's flagship product, the MIRA (Miniaturized In vivo Robotic Assistant) Platform, is a pioneering device that aims to streamline surgical procedures by allowing for quick setup in the operating room without the need for heavy equipment. This technology is intended to assist surgeons in improving clinical outcomes while also addressing healthcare costs. Virtual Incision's approach represents a significant advancement in robotic-assisted surgery, with plans for future applications beyond colon resection.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Willow, founded in 2014 and based in Mountain View, California, is a company that specializes in the development and manufacturing of wearable breast pumps and related breastfeeding products. The company offers a range of items including in-bra breast pumps, milk bags, replacement parts, pumping bras, and accessories like flanges and chargers. Willow's breast pumps are designed to be mobile and hands-free, allowing mothers to pump discreetly and conveniently. The devices are cordless, spill-proof, and equipped with a mobile application that tracks milk output, facilitating a hassle-free pumping experience for mothers on the go.

CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.

Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

SOPHiA GENETICS is a healthcare technology company focused on advancing data-driven medicine and enhancing life sciences research. The company has developed the SOPHiA DDM™ Platform, a cloud-based software-as-a-service solution that analyzes complex multimodal data sets and various diagnostic modalities. This platform is utilized by over 780 hospitals, laboratories, and biopharma institutions worldwide. Headquartered in Switzerland, SOPHiA GENETICS also maintains a presence in France, the United States, and Brazil, underscoring its commitment to improving healthcare outcomes through innovative technology.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

IntelyCare, Inc. is a healthcare staffing company based in Quincy, Massachusetts, founded in 2014. It provides an on-demand staffing platform that connects nursing professionals with post-acute healthcare facilities, enabling them to optimize staffing levels and manage workforce demands effectively. The platform allows nurses and nursing assistants to create their own schedules and select shifts that suit them, fostering a flexible work environment. Utilizing advanced data science and artificial intelligence, IntelyCare automates scheduling and improves the efficiency of filling nursing shifts, achieving rates three times the industry average. The company serves a variety of clients, including home care agencies, assisted living facilities, long-term care establishments, and rehabilitation hospitals, ultimately aiming to reduce burnout among nursing staff and enhance overall productivity. IntelyCare operates as a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.

EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.

ReShape Medical Inc. specializes in non-surgical weight loss solutions aimed at individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30 to 40. The company offers the ReShape Integrated Dual Balloon System, which consists of two intragastric balloons that are placed in the stomach and filled with saline. This system is intended to assist patients in losing weight when combined with a medically supervised diet and exercise program. The procedure is designed for adults who have not achieved significant weight loss through diet and exercise alone. ReShape Medical also provides other weight management solutions, including the FDA-approved Lap-Band System and the investigational ReShape Vest System, which aim to support patients in their weight loss journeys while minimizing the need for invasive surgical procedures. Founded in 2005 and based in San Clemente, California, ReShape Medical operates as a subsidiary of EnteroMedics Inc.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Kobojo is a French startup established in 2008 that focuses on developing online games and applications aimed at engaging mid-core players. The company enhances traditional gaming experiences by incorporating a social dimension, allowing players to connect and compete with friends. Kobojo's offerings are accessible on various platforms, primarily through social networks, without the need for downloads. The games feature hand-drawn 2D graphics that provide an artistic flair, appealing to users who appreciate creative visuals. While currently available on platforms like Facebook and iPhone, Kobojo plans to expand its reach to additional social networks in the future.

SOPHiA GENETICS is a healthcare technology company focused on advancing data-driven medicine and enhancing life sciences research. The company has developed the SOPHiA DDM™ Platform, a cloud-based software-as-a-service solution that analyzes complex multimodal data sets and various diagnostic modalities. This platform is utilized by over 780 hospitals, laboratories, and biopharma institutions worldwide. Headquartered in Switzerland, SOPHiA GENETICS also maintains a presence in France, the United States, and Brazil, underscoring its commitment to improving healthcare outcomes through innovative technology.

Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

Quid, Inc. develops a platform that searches, analyzes, and visualizes collective intelligence to address strategic inquiries. Its software specializes in analyzing text-based data, utilizing advanced techniques such as implicit network analysis and graph theory to create interactive visualizations. Through proprietary algorithms that incorporate artificial intelligence and natural language processing, Quid efficiently uncovers insights from extensive datasets, including news articles, blog posts, company profiles, and patents. The platform is designed for non-technical users in enterprise organizations, enabling them to independently access valuable information and generate unique insights. Quid caters to various sectors, including marketing, public relations, consulting, technology, healthcare, and financial services. Founded in 2006 and headquartered in San Francisco, California, with additional offices in New York and London, Quid merged with NetBase Solutions in January 2020, forming a combined entity known as NetBase Quid.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Spartoo is a European online retailer headquartered in Grenoble, France, specializing in the sale of footwear and fashion items for men, women, and children. Founded in 2006, the company offers a diverse range of products, including trainers, boots, sandals, and various styles of shoes, alongside ready-to-wear clothing and leather goods. Spartoo operates an e-commerce platform that features not only footwear but also a variety of fashion items such as jeans, trousers, coats, and t-shirts. The company serves customers across several countries, including Germany, England, Italy, Spain, as well as the UK regions of England, Wales, Scotland, and Northern Ireland.

Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

Quid, Inc. develops a platform that searches, analyzes, and visualizes collective intelligence to address strategic inquiries. Its software specializes in analyzing text-based data, utilizing advanced techniques such as implicit network analysis and graph theory to create interactive visualizations. Through proprietary algorithms that incorporate artificial intelligence and natural language processing, Quid efficiently uncovers insights from extensive datasets, including news articles, blog posts, company profiles, and patents. The platform is designed for non-technical users in enterprise organizations, enabling them to independently access valuable information and generate unique insights. Quid caters to various sectors, including marketing, public relations, consulting, technology, healthcare, and financial services. Founded in 2006 and headquartered in San Francisco, California, with additional offices in New York and London, Quid merged with NetBase Solutions in January 2020, forming a combined entity known as NetBase Quid.

Kobojo is a French startup established in 2008 that focuses on developing online games and applications aimed at engaging mid-core players. The company enhances traditional gaming experiences by incorporating a social dimension, allowing players to connect and compete with friends. Kobojo's offerings are accessible on various platforms, primarily through social networks, without the need for downloads. The games feature hand-drawn 2D graphics that provide an artistic flair, appealing to users who appreciate creative visuals. While currently available on platforms like Facebook and iPhone, Kobojo plans to expand its reach to additional social networks in the future.

Retailo is a full-service provider in the prepaid and gift card industry, specializing in the distribution of gift cards across continental Europe. The company operates a third-party prepaid card network, offering a variety of products, including gift cards, virtual gift vouchers, and online shopping cards. These products are conveniently available at multiple points of sale, such as retail stores, flower shops, and petrol stations, allowing customers to purchase gift cards for special occasions. In addition to offline sales, Retailo also provides electronic vouchers that can be delivered via SMS or MMS through its website, catering to the growing demand for digital solutions in the gifting market.

SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

PneumRx, Inc. is a medical device company founded in 2004 and based in Mountain View, California. The company specializes in developing minimally invasive treatments specifically for patients suffering from emphysema. Its primary product is the RePneu Lung Volume Reduction Coil, an investigational device designed to improve lung function and quality of life for individuals affected by this chronic respiratory condition.

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

CXignited sets the new standard for Customer Experience (CX) igniting product, people and brand passion. Through its progressive ShopCX Cloud Platform, CXignited streams shop floor and Unified Commerce information intelligence through RFID/Beacons/IoT. With a Real-time Local Positioning System (RLPS), CXignited drives product digitalization, localization, personalization and authentication across the Omni-channel for luxury retailers and global brands.

Spartoo is a European online retailer headquartered in Grenoble, France, specializing in the sale of footwear and fashion items for men, women, and children. Founded in 2006, the company offers a diverse range of products, including trainers, boots, sandals, and various styles of shoes, alongside ready-to-wear clothing and leather goods. Spartoo operates an e-commerce platform that features not only footwear but also a variety of fashion items such as jeans, trousers, coats, and t-shirts. The company serves customers across several countries, including Germany, England, Italy, Spain, as well as the UK regions of England, Wales, Scotland, and Northern Ireland.

CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Lumavita is an independent, specialty biopharmaceutical company focused on global development and commercialisation of novel anti-infectives for women’s health. Lumavita is based in Basel, Switzerland, home to a significant and growing biopharmaceutical sector.

CommProve specializes in real-time Quality of Service (QoS) monitoring for wireless networks, having been established in 1996 by experts in network operations and software engineering. The company focuses on developing software that allows wireless operators to monitor and enhance their network performance and subscriber experience. Its platform facilitates real-time data acquisition and analysis, collecting information from both analogue and LTE mobile networks. By integrating this data with business rules and subscriber information, CommProve enables mobile network operators to gain insights into their operations, thereby improving financial performance and ensuring a high-quality user experience. The company's initial engagements with Tier 1 customers highlighted the necessity for effective measurement and reporting of subscriber experience through the radio link.

Retailo is a full-service provider in the prepaid and gift card industry, specializing in the distribution of gift cards across continental Europe. The company operates a third-party prepaid card network, offering a variety of products, including gift cards, virtual gift vouchers, and online shopping cards. These products are conveniently available at multiple points of sale, such as retail stores, flower shops, and petrol stations, allowing customers to purchase gift cards for special occasions. In addition to offline sales, Retailo also provides electronic vouchers that can be delivered via SMS or MMS through its website, catering to the growing demand for digital solutions in the gifting market.

Retailo is a full-service provider in the prepaid and gift card industry, specializing in the distribution of gift cards across continental Europe. The company operates a third-party prepaid card network, offering a variety of products, including gift cards, virtual gift vouchers, and online shopping cards. These products are conveniently available at multiple points of sale, such as retail stores, flower shops, and petrol stations, allowing customers to purchase gift cards for special occasions. In addition to offline sales, Retailo also provides electronic vouchers that can be delivered via SMS or MMS through its website, catering to the growing demand for digital solutions in the gifting market.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

CXignited sets the new standard for Customer Experience (CX) igniting product, people and brand passion. Through its progressive ShopCX Cloud Platform, CXignited streams shop floor and Unified Commerce information intelligence through RFID/Beacons/IoT. With a Real-time Local Positioning System (RLPS), CXignited drives product digitalization, localization, personalization and authentication across the Omni-channel for luxury retailers and global brands.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

CXignited sets the new standard for Customer Experience (CX) igniting product, people and brand passion. Through its progressive ShopCX Cloud Platform, CXignited streams shop floor and Unified Commerce information intelligence through RFID/Beacons/IoT. With a Real-time Local Positioning System (RLPS), CXignited drives product digitalization, localization, personalization and authentication across the Omni-channel for luxury retailers and global brands.